<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03844022</url>
  </required_header>
  <id_info>
    <org_study_id>H-18023049.1</org_study_id>
    <nct_id>NCT03844022</nct_id>
  </id_info>
  <brief_title>MRI in McArdle Disease (GSDV)</brief_title>
  <official_title>MRI in McArdle Disease (Glycogen Storage Disease Type V)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Rigshospitalet, Denmark</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Rigshospitalet, Denmark</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this study is to describe the degree of muscle wasting in patients with McArdle
      disease judged by MRI, quantitative magnetic resonance (DIXON) and T1 weighted images, and
      muscle strength, collected across multiple European sites and compared to healthy controls.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 1, 2018</start_date>
  <completion_date type="Anticipated">December 1, 2020</completion_date>
  <primary_completion_date type="Anticipated">December 1, 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Cross-Sectional</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>DIXON MRI</measure>
    <time_frame>1 time</time_frame>
    <description>Whole body quantitative muscle fat fraction analyses (DIXON)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Muscle strength</measure>
    <time_frame>1 time</time_frame>
    <description>MRC scale</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>T1 MRI</measure>
    <time_frame>1 time</time_frame>
    <description>Whole body qualitative muscle fat fraction analyses (T1)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Back pain questionnaire</measure>
    <time_frame>1 time</time_frame>
    <description>Back pain questionnaire</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Glycogen Storage Disease Type V</condition>
  <arm_group>
    <arm_group_label>McArdle disease</arm_group_label>
    <description>Glycogen storage disease</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Healty controls</arm_group_label>
    <description>Age and gender matched</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>MRI</intervention_name>
    <description>magnetic resonance imaging</description>
    <arm_group_label>Healty controls</arm_group_label>
    <arm_group_label>McArdle disease</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        McArdle disease (GSDV) Healthy controls
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  GSDV or healthy controls

        Exclusion Criteria:

          -  MRI contradictions
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Copenhagen Neuromuscular Center, Rigshospitalet</name>
      <address>
        <city>Copenhagen</city>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nicoline Løkken</last_name>
      <phone>+45 3545 8748</phone>
      <email>nicolineloekken@regionh.dk</email>
    </contact>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <verification_date>November 2019</verification_date>
  <study_first_submitted>December 12, 2018</study_first_submitted>
  <study_first_submitted_qc>February 15, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">February 18, 2019</study_first_posted>
  <last_update_submitted>November 26, 2019</last_update_submitted>
  <last_update_submitted_qc>November 26, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">November 27, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Rigshospitalet, Denmark</investigator_affiliation>
    <investigator_full_name>Nicoline Løkken</investigator_full_name>
    <investigator_title>MD, Research fellow</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glycogen Storage Disease</mesh_term>
    <mesh_term>Glycogen Storage Disease Type V</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

